Search results for CD20

Odronextamab Biosimilar – Anti-CD3, CD20 mAb – Research Grade, ProteoGenix, PX-TA1599

Description of Odronextamab Biosimilar - Anti-CD3, CD20 mAb - Research Grade Introduction: Odronextamab is a biosimilar antibody that targets both CD3 and CD20, making it a promising therapeutic option for various diseases. In this article, we will delve into the structure, activity, and potential applications of this unique antibody. Structure of Odronextamab: Odronextamab is a bispecific antibody, meaning it has two binding sites that can recognize and bind to two different targets. It is composed of two monoclonal antibodies, one targeting CD3 and the other targeting CD20, linked together by a flexible linker. This structure allows for simultaneous binding to both CD3 and CD20, leading to a potent and targeted immune response. Activity of Odronextamab: Odronextamab has a dual mechanism of action, making it a highly effective therapeutic agent. By binding to CD3, it activates T cells and stimulates their proliferation, leading to a robust immune response. At the same time, by binding to CD20, it triggers the destruction of B cells, which are involved in various autoimmune and malignant diseases. This dual activity makes Odronextamab a versatile and potent therapeutic option. Applications of Odronextamab: 1. Treatment of Autoimmune Diseases: Autoimmune diseases occur when the immune system mistakenly attacks healthy cells and tissues. Odronextamab, with its dual activity, can effectively target both T and B cells involved in autoimmune diseases such as rheumatoid arthritis, multiple sclerosis, and lupus. By suppressing the overactive immune response, Odronextamab can help alleviate the symptoms and improve the quality of life for patients with these conditions. 2. Cancer Therapy: CD20 is a protein found on the surface of B cells, which are involved in the development of various types of cancer, including lymphoma and leukemia. By targeting CD20, Odronextamab can effectively destroy these cancerous B cells, leading to tumor regression and improved patient outcomes. Additionally, the activation of T cells by CD3 binding can also enhance the immune response against cancer cells, making Odronextamab a promising option for cancer therapy. 3. Transplant Rejection Prevention: One of the major challenges in organ transplantation is the risk of rejection by the recipient’s immune system. Odronextamab can be used as an immunosuppressant to prevent transplant rejection by targeting and suppressing T cell activity. This can increase the success rate of organ transplantation and improve patient outcomes. 4. Treatment of Hematological Disorders: Hematological disorders, such as certain types of anemia and thrombocytopenia, are characterized by abnormal levels of blood cells. Odronextamab can be used to target and destroy specific types of B cells involved in these disorders, leading to the restoration of normal blood cell levels. Conclusion: In summary, Odronextamab is a promising biosimilar antibody with a unique structure and dual activity against CD3 and CD20. Its potential applications in various diseases, including autoimmune disorders, cancer, transplant rejection, and hematological disorders, make it a versatile and potent therapeutic option. Further research and clinical trials are needed to fully explore the potential of Odronextamab in the treatment of these diseases.

Ofatumumab Biosimilar – Anti-MS4A1, CD20 mAb – Research Grade, ProteoGenix, PX-TA1146

Description of Ofatumumab Biosimilar - Anti-MS4A1, CD20 mAb - Research Grade Introduction Ofatumumab Biosimilar is a monoclonal antibody (mAb) that targets the protein CD20 on the surface of B-cells. It is a biosimilar of the original drug, Ofatumumab, and has been developed for research purposes. In this article, we will discuss the structure, activity, and potential applications of this biosimilar in the field of medicine. Structure Ofatumumab Biosimilar is a fully humanized IgG1 kappa monoclonal antibody. It is composed of two identical heavy chains and two identical light chains, each with a molecular weight of approximately 150 kDa. The antibody has a Y-shaped structure, with two antigen-binding fragments (Fab) and one crystallizable fragment (Fc). The Fab regions are responsible for binding to the CD20 protein, while the Fc region plays a role in immune effector functions. Activity The primary activity of Ofatumumab Biosimilar is to target and bind to the CD20 protein on the surface of B-cells. This binding leads to the depletion of B-cells through various mechanisms, including antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and direct induction of apoptosis. By depleting B-cells, Ofatumumab Biosimilar can modulate the immune response and potentially treat various diseases. Targeting CD20 CD20 is a transmembrane protein expressed on the surface of B-cells, including both normal and malignant B-cells. It plays a crucial role in the development and differentiation of B-cells. However, in certain diseases, such as B-cell lymphomas and autoimmune disorders, CD20 becomes overexpressed, leading to abnormal B-cell proliferation. Ofatumumab Biosimilar specifically targets CD20, leading to the depletion of these abnormal B-cells and potentially treating these diseases. Immune Effector Functions In addition to targeting CD20, Ofatumumab Biosimilar can also activate immune effector functions through its Fc region. The Fc region can bind to Fc receptors on the surface of immune cells, such as natural killer (NK) cells and macrophages, triggering ADCC and CDC. This results in the destruction of B-cells and further modulates the immune response. Applications Ofatumumab Biosimilar has potential applications in the field of medicine, particularly in the treatment of B-cell-related disorders. Some of the diseases that could potentially benefit from this biosimilar include: B-cell Lymphomas B-cell lymphomas are a group of cancers that originate from abnormal B-cells. Ofatumumab Biosimilar can target and deplete these abnormal B-cells, potentially treating B-cell lymphomas. It has shown promising results in clinical trials for the treatment of chronic lymphocytic leukemia (CLL) and follicular lymphoma. Autoimmune Disorders Autoimmune disorders, such as rheumatoid arthritis, multiple sclerosis, and systemic lupus erythematosus, are characterized by an overactive immune response. Ofatumumab Biosimilar can modulate the immune response by depleting B-cells, potentially treating these disorders. It has shown efficacy in clinical trials for the treatment of rheumatoid arthritis and multiple sclerosis. Organ Transplant Rejection Organ transplant rejection occurs when the immune system recognizes the transplanted organ as foreign and attacks it. B-cells play a role in this process by producing antibodies against the transplanted organ. Ofatumumab Biosimilar can deplete these B-cells and potentially prevent organ transplant rejection. Future Potential In addition to the above applications, Ofatumumab Biosimilar is also being studied for its potential in treating other diseases, such as autoimmune hemolytic anemia and pemphigus vulgaris. It may also have a role in combination therapy with other drugs for the treatment of certain cancers. Conclusion

CD20 (2H7) Mouse Monoclonal Antibody (APC Conjugate)#69077, Cell Signaling Technology (CST), 69077

CD20 (2H7) Mouse Monoclonal Antibody (APC Conjugate) recognizes endogenous levels of total CD20 protein. This antibody conjugate detects an epitope within the extracellular domain.

Anti-Human CD20/MS4A1 Antibody (2H7), APC (HY257437), abinScience, HY257437

Anti-Human CD20/MS4A1 Antibody (SAA0006), APC (HY257137), abinScience, HY257137

Anti-Human CD20/MS4A1 Antibody (SAA1414), FITC (HY257317), abinScience, HY257317

Anti-Human CD20/MS4A1 Antibody (SAA0007), PerCP (HY257247), abinScience, HY257247

Anti-Human CD20/MS4A1 Antibody (2H7), PE (HY257427), abinScience, HY257427

Anti-Human CD20/MS4A1 Antibody (SAA2209), PerCP (HY257647), abinScience, HY257647

Anti-Human CD20/MS4A1 Antibody (SAA2209), APC (HY257637), abinScience, HY257637